Neuroimaging and CSF Biomarkers
Neuroimaging and CSF Biomarkers supports researchers and clinicians developing and validating biomarkers to advance drug development, diagnosis, and monitoring for Alzheimer's disease and related dementias.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: December 7, 2026 (Invited Full Proposal)
Funding Amounts: Up to $600,000 for one year, with potential for follow-on funding
Summary: Supports development and validation of neuroimaging, CSF, and functional biomarkers that advance drug development for Alzheimer's disease and related dementias.
Key Information: Funding uses mission-related investments requiring returns based on scientific and/or business milestones.
Description
The Alzheimer's Drug Discovery Foundation (ADDF) supports further development and validation of established biomarkers with a clear clinical need in Alzheimer's disease and related dementias. The program prioritizes a defined clinical context of use, advantages over existing biomarkers, and a path to commercialization or clinical adoption. Supported approaches include novel PET ligands, CSF biomarkers, innovative MRI approaches validated in larger cohorts, and novel functional measures such as EEG, MEG, and TMS.
The emphasis is on tools that demonstrate therapeutic target engagement, detect disease earlier, monitor progression, predict cognitive decline, and distinguish dementia subtypes for clinical-trial stratification. Neuroinflammation, synaptic integrity, autophagy, and TDP-43 are high priorities. Companion biomarkers for therapies already in development receive particular priority.
